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Abstract
Introduction: Following the implementation of the provision of lifelong antiretroviral therapy to all HIV-positive pregnant or
breastfeeding women for prevention of mother-to-child transmission (PMTCT) of HIV by the Kingdom of Lesotho in 2013, we
assessed the effectiveness of this approach by evaluating 24-month HIV-free survival among HIV-exposed infants (HEIs).
Methods: We conducted a prospective observational cohort study that enrolled HIV-positive and HIV-negative pregnant
women, with follow-up of women and their infants for 24 months after delivery. Participant recruitment started in June 2014
and follow-up ended in September 2018. Trained nurses collected study information through patient interviews and chart
abstraction at enrolment and every three to six months thereafter. Maternal HIV testing, infant mortality, HIV transmission
and HIV-free survival rates were computed using Kaplan–Meier estimation. Cox regression hazard models were used to iden-
tify factors associated with infant HIV infection and death.
Results: Between June 2014 and February 2016, we enrolled 653 HIV-positive and 941 HIV-negative pregnant women.
Twenty-seven HIV-negative women acquired HIV during follow-up. Ultimately, 634 liveborn HEI (382 (52%) male, 303 (48%)
female, 3 missing) and 839 who remained HIV-unexposed (HUIs) (409 (49.0%) male, 426 (51.0%) female, 4 missing) were fol-
lowed; 550 HEIs and 701 HUIs completed the 24-month follow-up period. Of 607 (95.7%) HEIs who were tested for HIV at
least once during follow-up, 17 were found to be HIV-positive. Two (9.5%) of 21 infants born to mothers who acquired HIV
infection during follow-up were HIV-positive compared to 15 (2.4%) of 613 HEI born to women with known HIV infection.
The risk of HIV transmission from HIV-positive mothers to their infants by 24 months of age was 2.9% (95% CI: 1.8 to 4.7).
The estimated 24-month mortality rate among HEIs was 6.0% (95% CI: 4.4 to 8.2) compared to 3.8% (95% CI: 2.6 to 5.3)
among HUIs (Log-rank p = 0.065). HIV-free survival at 24 months was 91.8% (95% CI: 89.2 to 93.7). Lower maternal age and
birth weight were independently associated with increased HIV infection or death of infants.
Conclusions: The implementation of lifelong ART for PMTCT in the Lesotho public health system resulted in low HIV trans-
mission, but survival of HEI remains lower than their HIV uninfected counterparts.
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1 | INTRODUCTION
The HIV epidemic in children is largely due to mother-to-child
HIV transmission (MTCT). In 2018, the Joint United Nations
Program on HIV/AIDS (UNAIDS), estimated that 160,000 new
HIV infections occurred among children [1]. Without treat-
ment, approximately one-half of HIV-infected children in sub-
Saharan Africa die before their second birthday [2,3]. Prevent-
ing new infections and providing early treatment to infected
infants are essential strategies for controlling the HIV epi-
demic in infants and children [3].
Over the last two decades, strategies for the prevention of
mother-to-child HIV transmission (PMTCT) have evolved to
include maternal use of highly active antiretroviral drugs [4].
The implementation of these PMTCT strategies has led to
tremendous success in the prevention of new infections
among children [5-7]. In 2013, the World Health Organization
(WHO) released new guidelines on the use of antiretroviral
drugs for the treatment of pregnant women and the preven-
tion of HIV infection in infants [8]. These guidelines, initially
known as Option B+, recommended lifelong antiretroviral
therapy (ART) for all pregnant and breastfeeding women with
a six-week administration of daily nevirapine to the infant.
In settings where this PMTCT strategy is fully implemented,
a substantial reduction in new HIV infections has been real-
ized. There is clear evidence showing improved HIV-free sur-
vival for infants tested at six weeks of age [9-11]; however,
there is limited information on the long-term effectiveness of
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this strategy among breastfeeding populations in high HIV
prevalence settings where infants often continue to be
exposed to HIV throughout the first two years of life. In
2013, the Kingdom of Lesotho, with an HIV prevalence of
25.8% among pregnant women, adopted these WHO guide-
lines.
The PMTCT Program Effectiveness among Women and
Infants in Lesotho (PEA-WIL) study aimed to evaluate the
effectiveness of PMTCT service delivery and assess progress
towards the virtual elimination of mother-to-child HIV trans-
mission (EMTCT) in selected districts of Lesotho [12]. This
paper presents findings on 24-month HIV-free survival among
HEI, factors associated with infant HIV infection and death,
and compares survival among HEI and HUI.
2 | METHODS
2.1 | Study design
This was a prospective observational cohort study that involved
the recruitment and follow-up of pregnant women attending
antenatal care (ANC) clinics at selected health facilities in
Lesotho. We recruited HIV-positive and HIV-negative pregnant
women and followed them during pregnancy up to 24 months
postpartum. Infants born to these women were followed along
with their mothers for the 2-year period after delivery.
2.2 | Study setting
During the study period, health facilities provided routine
PMTCT services to all pregnant women as part of general
ANC. Pregnant women were offered opt-out HIV screening
followed by ART initiation if the women tested HIV positive.
HIV-negative women received repeat HIV tests at 36 weeks
of pregnancy or delivery, and in the postnatal period. Based
on the national PMTCT guidelines, the preferred ART regimen
was a fixed-dose combination of tenofovir disoproxil fumarate,
lamivudine and efavirenz administered once daily. HIV viral
load monitoring was carried out every six months, and women
found to have viral load results <1000 copies/mL were consid-
ered virally suppressed.
HEIs were initiated on daily nevirapine from birth to six
weeks of age and on daily cotrimoxazole from six weeks of
age until HIV infection was definitively excluded. Exclusive
breastfeeding for the first six months of life was encouraged.
To assess HIV infection in the infant, HIV DNA PCR tests
were carried out at four and fourteen weeks of infant age.
Infants with negative DNA PCR results were subsequently re-
tested using WHO-recommended rapid antibody tests at nine
months, with confirmatory DNA PCR testing if positive.
Infants with negative HIV test results at nine months,
received a rapid antibody test at 18 months of age or six
weeks after cessation of breastfeeding. HIV-positive infants
were initiated on ART.
2.3 | Study sites and participants
Between June 2014 and February 2016, we consecutively
enrolled pregnant women from 14 health facilities (five hospi-
tals and nine health centres) located in three of Lesotho’s ten
districts. These health facilities represented all hospitals and a
random selection of medium (100 to 200 ANC attendees/
year) and high volume (>200 ANC attendees/year) health cen-
tres in the three districts.
To be enrolled in the study, pregnant women had to be
attending ANC at a study facility, reside within the facility
catchment area, and be willing to provide written informed
consent. There was no age restriction for study enrolment as
young pregnant women in Lesotho are considered emanci-
pated and therefore provided their own consent for participa-
tion. Women who temporarily received care from the health
facility were excluded. Infants were automatically eligible for
enrolment at birth.
Infants were considered HIV exposed if their mothers were
found to be HIV positive during pregnancy, delivery or during
the breastfeeding period, including infants born to HIV-nega-
tive women who seroconverted during follow-up.
2.4 | Study procedures
Study-specific information was obtained at enrolment, around
the time of delivery, and every three months postpartum. Ges-
tational age at enrolment was determined based on the date
of the last menstrual period. Trained study nurses interviewed
the women and abstracted additional study information from
the medical records using structured data collection forms.
The nurses reviewed participant medical records and
abstracted information on general health and clinical/labora-
tory history of infants, birth history, hospitalizations, ARV use
and toxicity, retention in care, infant feeding practices and
infant growth. Relevant information on deliveries or admis-
sions that occurred in non-study facilities, was extracted from
the participant’s medical booklet upon return to the study
facility. At every visit, participants were interviewed to assess
adherence to ART in the seven days preceding the visits. In
addition, we conducted study-specific HIV DNA PCR testing
at birth and at six months, and a final rapid antibody test on
all exposed children at 24 months of age.
HIV-unexposed infants (HUIs) were assessed every three to
six months when their mothers returned to the clinics for
postnatal care and HIV re-testing. Women were re-tested
every three months until 12 months postpartum and at 18
and 24 months postpartum. HIV-negative women who sero-
converted during follow-up were started on ART and their
infants tested for possible HIV infection. At every study visit,
study nurses collected information on infant feeding practices.
For children who died during follow-up, mortality informa-
tion was obtained through chart abstraction at the health
facilities. Information on date of death, the primary cause of
death and medication given to the child at the time of death
was abstracted. For deaths that occurred outside health facili-
ties, parents or caregivers were interviewed to determine
events at the time of death.
2.5 | Statistical analysis
We summarized maternal and infant characteristics at delivery
using frequencies and proportions by infant HIV exposure sta-
tus. Continuous variables were summarized using means
(SD) or medians (range) by exposure status. We also summa-
rized and compared 24-month infant outcomes using fre-
quencies and proportions with associated 95% confidence
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intervals. Chi-square tests were used to test for significant dif-
ferences between HIV-exposed and -unexposed infants.
For each infant who did not die during follow-up, we calcu-
lated the time at risk of death from birth to the last follow-up
date. For infants who died, their time at risk for death was
calculated as the difference between date of birth and date of
death. We created an indicator variable for death, with those
who did not die censored at the last known follow-up date.
The HIV infection risk time was calculated only among HIV-ex-
posed infants who had at least one HIV test. For infants who
were not infected, the time at risk for HIV infection was cal-
culated as the difference between the date of birth and the
date of last HIV-negative test. For infants who became
infected with HIV, their time at risk for HIV infection was cal-
culated as the difference between the date of birth and the
date of the first HIV-positive test. An HIV infection indicator
variable was created with infants who were not infected cen-
sored at the last HIV-negative test date. We created an indi-
cator for HIV-free survival based on either death or HIV
infection and the HIV-free survival time was calculated as the
minimum time between being at risk of death and at risk for
HIV infection.
We estimated infant mortality, MTCT and HIV-free survival
rates over time using Kaplan Meier estimation. Kaplan Meier
graphs were used to describe mortality, infection and survival
patterns over time. We used Wilcoxon log-rank tests to com-
pare the survival curves between HIV-exposed and unexposed
infants.
We estimated the proportion of infants who died or were
infected by the different categories of maternal and infant
characteristics assessed at delivery. We used univariate Cox
regression to identify factors associated with infant death or
HIV infection. Factors that were significantly associated with
infant death or HIV infection in the unadjusted analyses were
included in a multivariate Cox regression model to identify
independent factors associated with death or HIV infection.
The strength of the association was expressed as adjusted
hazard ratios and associated 95% confidence intervals. All sta-
tistical analyses were performed using Stata version 15.1 (Col-
lege Station, TX, USA).
2.6 | Ethical considerations
This study was approved by the Lesotho National Health
Research Ethics Committee, the Baylor College of Medicine
Children’s Foundation Lesotho Institutional Review Board
(IRB), and the George Washington University IRB. Written
informed consent was obtained from the mothers for their
own participation and the participation of their infants. All
study team members were trained on the protection of
human subjects.
3 | RESULTS
A total of 1594 pregnant women were enrolled in the
study, of which 653 (41.0%) were HIV positive and 941
(59.0%) were HIV negative. By the time of delivery, eight
HIV-negative women had sero-converted to become HIV
positive. Birth information was available for 631 infants that
were HIV exposed by delivery (613 (97.1%) liveborn, 18
(2.9%) stillborn) and 879 HIV unexposed infants (860
(97.8%) liveborn, 19 (2.2%) stillborn) (Figure 1). This
includes eight sets of HEI twins and 11 sets of HUI twins.
During the postpartum follow-up period, an additional 19
HIV-negative women with 21 children seroconverted. Alto-
gether, 634 liveborn infants (328 (52.0%) male, 303 (48%)
female, 3 missing) were HIV exposed. 24-month outcomes
were available for 588 HEI (550 (93.5%) alive and 38
(6.5%) died) and 733 HUI (701 (95.6%) alive and 32 (4.4%)
died) with 87% of eligible HEI having a 24-month final HIV
test done.
Overall, 45.5% of mothers was under age 25 years; of the
19 women who seroconverted after delivery, 84% was under
age 25 years (Table 1). The proportion of women who dis-
closed their HIV status to someone was 74.4%, with 66.7%
disclosing to their partner/spouse. At delivery, 96.9% of moth-
ers of HIV-exposed infants was on ART (median time on
ART = 6.6 months; IQR: 4 to 31.6 months). Of 595 HIV-ex-
posed infants with information on infant antiretroviral prophy-
laxis, 576 (96.8%) were initiated on nevirapine, with the
majority of infants initiating prophylaxis within the first
72 hours of life. About 50% of HIV-exposed and unexposed
infants with information available on breastfeeding practices
was exclusively breastfed for the first six months of life. Mixed
feeding in the first six months of life was reported in 218/551
(39.6%) HIV-exposed infants and 337/705 (47.8%) HIV-unex-
posed infants.
During the 24-month follow-up period, 38 (6.0%) HIV-ex-
posed infants died compared to 31 (3.7%) HIV-unexposed
infants (chi-square p = 0.039) (Table 2).
The diagnosis preceding death is as shown in Table 3
below.
A total of 607 (95.7%) HIV-exposed infants were tested
for HIV at least once during follow-up. Of these, 17 (2.8%)
were HIV infected. Four of the 17 infants were diagnosed at
birth (in utero infection rate, 0.7%). Two (9.5%) of the 21
infants born to mothers who acquired HIV infection during
follow-up were HIV infected compared to 15 (2.4%) of 613
HEI tested at birth who were born to women with known
HIV infection. All HIV-positive infants were put on ART.
Table 4 shows the estimated mortality, HIV transmission and
HIV-free survival rates over time by exposure status. The
estimated 24-month mortality rate among HIV-exposed
infants was 6.0% (95% CI: 4.4 to 8.2) compared to 3.8%
(95% CI: 2.6 to 5.3) among HIV-unexposed infants (Log-rank
p = 0.065). The overall estimated risk of HIV transmission
from HIV-positive mothers to their infants was 2.9% (95%
CI: 1.8 to 4.7).
Figure 2 displays Kaplan–Meier curves of mortality, HIV
transmission and HIV-free survival for the infants by HIV
exposure status. Mortality is high during the first two months
of life for both HIV-exposed and HIV-unexposed infants but
thereafter, mortality among HEIs is markedly higher than mor-
tality in HUIs. The rate of in utero infection was low, 0.7%,
with most infection occurring during the postnatal period
through age 12 months.
In unadjusted models, younger maternal age, lack of viral
suppression, lower birth weight, and prematurity were inde-
pendently associated with increased HIV infection or death of
HEI (Table 5). Marital status, maternal education, disclosure of
HIV status to someone else or husband, being on ART at
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delivery, delivery mode, type of infant feeding, sex of child and
ARV prophylaxis were not associated with the hazard of HIV
infection or death.
After model adjustment, however, only maternal age, birth
weight and infant maturity at birth remained independently
associated with HIV infection or death of the infant. Children
of women <25 years of age were more likely to be HIV-posi-
tive or die compared to children of women ≥25 years (Hazard
ratio (HR) = 2.51, 95% CI: 1.29 to 4.87). Among infants born
to adolescent and young women (14-24 years), 25 (14.4%)
were infected or died compared to 27 (5.8%) infants born to
older women (25 to 45 years).
Figure 1. Child follow-up and HIV testing from birth to 24 months postpartum. Note: *LTFU = Loss to follow-up;** 1 additional child death
in each group with unknown age at death.
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Table 1. Maternal and infant characteristics by child HIV exposure status among liveborn infants
Characteristic
HIV exposed at delivery HIV exposed during follow-up HIV unexposed
Totaln (%) n (%) n (%)
Characteristics of mothers of liveborn infants
Number of mothers with delivery information 607 19 830 1456
Age at delivery in years median (range) 29 (17 to 45) 21 (15 to 28) 23 (14 to 45) 25 (21 to 31)
Age group (years)
14 to 24 158 (26.2%) 16 (84.2%) 487 (58.7%) 661 (45.5%)
25 to 45 446 (73.8%) 3 (15.8%) 343 (41.3%) 792 (54.5%)
Marital status
Married/living with partner 492 (81.5%) 14 (73.7%) 719 (86.6%) 1225 (84.3)
Never married 70 (11.6%) 4 (21.1%) 106 (12.8%) 180 (12.4)
Divorced/widowed 42 (7.0%) 1 (5.3%) 5 (0.6%) 48 (3.3)
Education
Primary or less 265 (43.9%) 5 (26.3%) 278 (33.5%) 548 (37.7)
Secondary 202 (33.4%) 10 (52.6%) 314 (37.8%) 526 (36.2)
High school 97 (16.1%) 4 (21.1%) 175 (21.1%) 276 (19.0)
Tertiary 40 (6.6%) 0 63 (7.6%) 103 (7.1)
HIV status disclosure (at any time)
Disclosed to someone 518 (85.8%) 11 (57.9%) 552 (66.5%) 1081 (74.4)
No disclosure 86 (14.2%) 8 (42.1%) 278 (33.5%) 372 (25.6)
HIV status disclosure to husband/partner
Disclosed 353 (74.5%) 7 (50.0%) 445 (61.9%) 805 (66.7)
Did not disclose 121 (25.5%) 7 (50.0%) 274 (38.1%) 402 (33.3)
On ART at delivery or during follow-up
Yes 588 (96.9%) 13 (61.9%) NA
No 19 (3.1%) 8 (38.1%)
Delivery mode
Vaginal 511 (84.7%) 13 (68.4%) 717 (86.8%) 1241 (85.7)
Cesarean 92 (15.3%) 6 (31.6%) 109 (13.2%) 207 (14.3)
Viral suppression (during entire follow-up period)
Suppressed (<1000 copies/mL) 358 (60.2%) 3 (25.0%) NA 361 (59.5)
Not suppressed 237 (39.8%) 9 (75.0%) 246 (40.5)
Infant characteristics
Number of live infant births 613 21 839 1473
Sex
Male 314 (51.5%) 14 (66.7%) 409 (49.0%) 737 (50.3%)
Female 296 (48.5%) 7 (33.3%) 426 (51.0%) 729 (49.7%)
Infant feeding in first 6 months
Exclusive breast feeding 279 (52.0%) 6 (40%) 349 (49.5%)
Exclusive alternatives to breast feeding 47 (8.8%) 1 (6.7%) 19 (2.7%)
Mixed feeding 210 (39.2%) 8 (53.3%) 337 (47.8%)
Infant initiated on ARV prophylaxis
Yes 576 (96.8%) NA NA
No 19 (3.2%)
ARV prophylaxis initiated within 72 hours
Yes 560 (94.8%) NA NA
No 31 (5.2%)
Birth weight in kg 3.03 (0.52) 3.02 (0.69) 3.12 (0.53) 3.08 (0.53)
mean (SD)
Birth weight category
<2.5 kg 59 (10.4%) 4 (23.5%) 65 (8.3%) 128 (9.3)
>2.5 kg 511 (89.6%) 13 (76.5%) 718 (91.7%) 1242 (90.7)
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For every 100-gram increase in birth weight, the risk of
HIV infection or death in infants decreased by 7% (HR = 0.93,
95% CI: 0.86 to 0.99); and preterm infants had a higher risk
of infection or death compared to term infants (HR = 3.11,
95% CI 1.12 to 8.65).
4 | DISCUSSION
Our results show that mother-to-child transmission of HIV by
24 months of age is 2.9% and HIV-free survival among HEIs
in the public healthcare setting of Lesotho is 91.8%. These
results demonstrate the effectiveness of universal, lifelong
ART implemented among breastfeeding communities residing
in a high HIV-prevalence setting, and are consistent with find-
ings of a similar study conducted in urban Kigali, Rwanda
between 2013 and 2016 in which Gill et al reported a 24-
month HIV transmission of 2.2% and an HIV-free survival rate
of 93.2% [7].
Several studies conducted within sub-Saharan Africa have
assessed HIV-free survival up to six weeks of infant age [9-
11,13]. Outcomes at six weeks of infant age reflect the trans-
mission that occurs during pregnancy and the peripartum per-
iod but fail to show the outcomes of continued HIV exposure
that occurs during the breastfeeding period. In many sub-
Saharan African settings, women breastfeed their babies
throughout the first year of life and often through the second
year [13]. The results of our study are noteworthy since they
cover the entire breastfeeding period and take into considera-
tion the diverse infant feeding practices. Mixed feeding,
though practised by a number of women in our cohort, was
not associated with HIV transmission. A community-based
cohort study conducted in rural Zambia reported an HIV-free
survival of 96.3% at 12 months of infant age, slightly higher
than found in this study [15]. In Zimbabwe, serial cross-sec-
tional community-based sero-surveys that evaluated the
PMTCT effectiveness at nine to eighteen months of infant
age, showed a 10% MTCT rate and HIV-free survival of
89.6% in 2012, with a 2014 repeat survey showing a reduc-
tion in MTCT to 4.8% and an increase in HIV-free survival to
95.1% with the WHO Option A PMTCT strategy [16].
For PMTCT programmes to be effective in reducing infec-
tion and death among infants, a “cascade” of PMTCT services
needs to be effectively delivered and accessed during antena-
tal care, delivery, and in the postnatal period. These services
include mother and partner HIV testing and counselling, and if
HIV positive, initiation and retention on ART; prompt initiation
of antiretroviral prophylaxis for the HEI once born, and infant
HIV testing at six weeks of age and subsequent time points if
HIV negative until six weeks after discontinuation of breast-
feeding [17,18]. In addition, prevention counselling and repeat
tests need to be carried out on HIV-negative mothers with
immediate initiation of ART whenever HIV is diagnosed and
testing of the child if breastfed.
Due to challenges in the healthcare system in many sub-
Saharan African countries like Lesotho, these proven interven-
tions are seldom fully implemented. In many settings, only a
proportion of women receives ANC at health facilities and
these services are often sought late in pregnancy or at deliv-
ery [19]. The results reported here clearly demonstrate that
the implementation of universal maternal ART markedly
Table 1. (Continued)
Characteristic
HIV exposed at delivery HIV exposed during follow-up HIV unexposed
Totaln (%) n (%) n (%)
Infant maturity at birth
Term 568 (93.3%) 20 (100%) 803 (96.6%) 1391 (95.3)
Pre-terma 41 (6.7%) 0 28 (3.4%) 69 (4.7)
a
Preterm = Born alive before 37 completed weeks of gestation.
Table 2. Infant outcomes by final HIV exposure status
Outcome
HIV exposed HIV unexposed p-value
N (%) N (%)
Total live births 634 839
Died 38 (6.0%) 31 (3.7%) 0.039
HIV infected 17/607 (2.8%) 0 –
Died or HIV infected 52 (8.2%) 31 (3.7%) <0.001
HIV-free survivala 581 (91.8%) 806 (96.3%)
a
HIV-free survival could not be determined for 3 infants (1 HEI and 2
HUI) with missing data









Diarrhoea and vomiting 5 2 7
Neonatal sepsis 5 2 7











Accidental drowning 0 1 1
Intestinal obstruction 0 2 2
Unknown 14 9 23
Total 38 31 69
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reduces MTCT even in non-ideal public health settings where
ANC and postnatal services are suboptimal.
For the HEI, prevention of HIV transmission from the
mother largely depends on the mother’s ability and willing-
ness to initiate and continue with lifelong ART and on her
adherence to treatment to maintain sustained virological sup-
pression. When mothers do not adhere to treatment or
become lost to follow-up, treatment interruptions occur that
lead to an increase in the risk of HIV transmission to the
infant [20-22]. In addition, HIV-negative mothers who acquire
infection during pregnancy risk transmitting the virus to their
infants. Acute HIV infection during pregnancy or
breastfeeding markedly increases the risk of MTCT of HIV
[23-26]. We found that HIV transmission was four times
higher in HIV-negative women who seroconverted compared
to women who were HIV positive at delivery. This under-
scores the need for additional protections for HIV negative
women during pregnancy and the breastfeeding period. Nev-
ertheless, the majority of the transmissions still occurred
among women who were known to be HIV positive at enrol-
ment. The suboptimal viral suppression seen in some of
these women may have contributed to the transmission.
Although not assessed, viral resistance to ART may have led
to the observed viraemia.














6 weeks 2.4 [1.5 to 4.0] 2.7 [1.8 to 4.1] 0.6 [0.3 to 1.8] 96.8 [95.1 to 97.9] 97.3 [95.9 to 98.2]
6 months 4.1 [2.8 to 6.0] 3.3 [2.3 to 4.8] 1.9 [1.0 to 3.4] 94.5 [92.3 to 96.0] 96.7 [95.2 to 97.7]
12 months 4.9 [3.5 to 7.0] 3.5 [2.4 to 5.0] 2.1 [1.2 to 3.6] 92.7 [90.4 to 94.5] 96.5 [95.0 to 97.6]
18 months 5.6 [4.1 to 7.8] 3.8 [2.6 to 5.3] 2.2 [1.3 to 3.8] 92.6 [90.1 to 94.4] 96.2 [94.7 to 97.4]
24 months 6.0 [4.4 to 8.2] 3.8 [2.6 to 5.3] 2.9 [1.8 to 4.7] 91.8 [89.2 to 93.7] 96.2 [94.7 to 97.4]
Log rank p 0.065 – <0.001
Figure 2. Kaplan-Meier graphs of child mortality, HIV transmission and HIV-free survival by HIV exposure status among liveborn infants.
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The significantly lower survival of HEIs compared to HUIs
in this study draws attention to the continued need for early
diagnosis followed by prompt initiation of ART for all HIV-pos-
itive children and close follow-up of all HIV-exposed
uninfected (HEU) children. These HEU infants and children
have in previous studies been found to have impaired growth
and higher infectious disease morbidity than their HIV-unex-
posed counterparts [27-29]. The underlying mechanisms
Table 5. Maternal and infant factors associated with infant’s HIV infection or death in exposed infants (N = 634)
Characteristic Total (n) Infected or died, n (%) Unadjusted HR [95% CI] Adjusted HR [95% CI] p-value
Maternal characteristics
Mother’s age (years)
14 to 24 174 25 (14.4%) 2.53 [1.45 to 4.44] 2.51 [1.29 to 4.87] 0.007
25 to 45 448 26 (5.8%) 1 1
Marital status
Married/living with partner 505 38 (7.5%) 1
Never married 74 10 (13.5%) 1.75 [0.85 to 3.64]
Divorced/widowed 43 3 (7.0%) 0.94 [0.29 to 3.04]
Education
Primary or less 269 26 (9.7%) 1
Secondary 212 15 (7.1%) 0.69 [0.36 to 1.33]
High school 101 8 (7.9%) 0.81 [0.37 to 1.81]
Tertiary 40 2 (5.0%) 0.54 [0.13 to 2.28]
HIV status disclosure
Disclosed to someone 528 39 (7.4%) 1
No disclosure 94 12 (12.8%) 1.89 [0.99 to 3.63]
Disclosure to husband/partner
Disclosed 400 27 (6.8%) 1 1
Did not disclose 222 24 (10.8%) 1.71 [0.98 to 3.0]
On ART at delivery
Yes 587 43 (7.3%) 1
No 18 3 (16.7%) 1.21 [0.17 to 8.79]
Viral suppression
Suppressed 361 19 (5.3%) 1 1
Not Suppressed 245 25 (10.2%) 2.05 [1.13 to 3.73] 1.81 [0.92 to 3.56] 0.089
Delivery mode
Vaginal 524 39 (7.4%) 1
Cesarean 98 10 (10.2%) 1.36 [0.68 to 2.72]
Infant characteristics
Sex
Male 324 19 (5.9%) 1 0.08
Female 297 29 (9.8%) 1.68 [0.94 to 2.99]
Infant feeding in first 6 months of life
Exclusive breast feeding 280 19 (6.8%) 1
Exclusive formula feeding 47 1 (2.1%) 0.29 [0.04 to 2.17]
Mixed feeding 216 10 (4.6%) 0.62 [0.29 to 1.34]
Initiated ARV prophylaxis
Yes 569 35 (6.2%) –
No 19 0
ARV prophylaxis within 72 hours
Yes 554 34 (6.1%) 1
No 30 1 (3.3%) 0.53 [0.07 to 3.84]
Birth weight (per 100 grams increase) 567 37 0.88 [0.84 to 0.92] 0.93 [0.86 to 0.99] 0.04
Maturity at birth
Term 581 39 (6.7%) 1 1
Preterma 39 10 (25.6%) 4.21 [2.10 to 8.42] 3.11 [1.12 to 8.65] 0.03
a
Preterm = Born alive before 37 completed weeks of gestation.
Tukei VJ et al. Journal of the International AIDS Society 2020, 23:e25648
http://onlinelibrary.wiley.com/doi/10.1002/jia2.25648/full | https://doi.org/10.1002/jia2.25648
8
leading to worse adverse outcomes in these group of HEI are
not fully known, but are likely to be a combination of several
factors including intrauterine growth retardation and preterm
birth, seen more often among HIV-exposed newborns [30],
immune dysfunction [31] and other adverse environmental
and socio-economic conditions.
Another important finding is the observed association
between maternal age and HIV infection or death in infants.
A significantly higher proportion of infants born to adoles-
cent or young women was infected or died compared to the
deaths or infections seen in infants of older women. As the
universal ART programme in Lesotho continues to mature,
there is a need to explore the underlying factors contributing
to the negative PMTCT outcomes seen among adolescent
girls and young women. A large study in Zimbabwe found
that adolescent pregnant women were less likely to know
their HIV status or be on ART prior to ANC attendance,
which could be one of the contributing factors [32]. To
improve child survival, there is a need to reinforce current
MCH and PMTCT efforts with appropriate interventions that
take into consideration the increased vulnerabilities seen
among these young mothers. In addition, these results high-
light the need to strengthen sexual and reproductive health
services for young women to prevent HIV acquisition and
pregnancy.
Our study had some limitations. We were only able to
assess HIV-free survival among infants born to women who
attended ANC services at health facilities. It is likely that
some pregnant women did not attend ANC or delivered at
home without visiting the facilities leading to an underestima-
tion of our study outcomes. We are therefore unable to esti-
mate HIV-free survival at the population level. In addition,
children who were lost to follow-up may have been infected
or died leading to underestimation of these outcomes. Infor-
mation on diagnoses preceding death of infants was, in some
cases, obtained from caregivers through phone interviews or
abstracted from patient records at the health facilities. The
accuracy of abstracted data depended on the information
recorded by the clinicians who saw the patients. It is possible
that some of the diagnoses were inaccurate. Post-mortem
examination of deceased infants was not conducted, making it
difficult to determine the cause of death. A number of women
had suboptimal viral suppression and our data on adherence
to ART had gaps and quality issues. We were unable to use it
in this analysis, and this may have limited our understanding
of the reasons for the high viral load seen. Despite these limi-
tations, our study provides promising results of PMTCT imple-
mentation from a region with the highest HIV prevalence in
the world.
5 | CONCLUSIONS
The implementation of universal ART in the Lesotho’s public
health system has markedly reduced HIV MTCT rates that
approached the global target of <2%. However, despite access
to ART, HIV-positive children still had lower survival than
their HIV-negative counterparts, as did HIV exposed but unin-
fected children. The results here provide additional evidence
on the effectiveness of current PMTCT strategies and under-
score the need for differentiated PMTCT interventions that
address the additional vulnerabilities encountered by infants
of adolescent and young women.
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